Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

Related Keywords

Texas ,United States ,Krinak Patel , ,Department Of Lymphoma Myeloma ,University Of Texas Md Anderson Cancer Center ,Division Of Cancer Medicine ,Cancer Medicine ,Cancer Center ,D ,Sc ,Fda Approval Of Ide Cel ,Patients With Triple Class Exposed Relapsed Refractory Multiple Myeloma ,